# US 2021/0171632 A1 · Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171632 A1
- Document ID: US20210171632A1
- Status: Published application
- Kind: A1
- Application number: 17/072,842
- Filed: 2020-10-16
- Published: 2021-06-10
- Earliest claimed: 2018-09-26
- Assignees: Lentigen Technology, Inc.
- Applicants: Lentigen Technology, Inc.
- Inventors: Dina Schneider; Rimas J. Orentas; Boro Dropulic; Peirong Hu
- Web page: https://patentgrep.com/patent/US20210171632A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4212: {CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2}
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding a CD19/CD22 tandem chimeric antigen receptor (CAR) comprising at least one extracellular antigen binding domain comprising a CD19/CD22 antigen binding domain, at least one transmembrane domain, and at least one intracellular signaling domain, wherein the CD19/CD22 tandem chimeric antigen receptor (CAR) is encoded by a nucleotide sequence comprising SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, or 82.

### Claim at position 2

-8. (canceled)

### Claim 9 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the the CAR is encoded by a nucleotide sequence consisting of SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, or 82.

### Claim 10 (depends on 1)

The isolated nucleic acid molecule of claim 1, wherein the CAR comprises the amino acid sequence of SEQ ID NO: 2, 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, or 83

### Claim at position 5

-13. (canceled)

### Claim 14 (depends on 1)

A chimeric antigen receptor (CAR) encoded by the isolated nucleic acid molecule of claim 1.

### Claim at position 7

-23. (canceled)

### Claim 24 (depends on 1)

A vector comprising a nucleic acid molecule of claim 1.

### Claim 25 (depends on 24)

The vector of claim 24, wherein the vector is selected from the group consisting of a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpes virus vector, a measles virus vector, a lentivirus vector, an adenoviral vector, or a retrovirus vector, or a combination thereof.

### Claim at position 10

-27. (canceled)

### Claim 28 (depends on 24)

An isolated cell comprising the vector of claim 24.

### Claim at position 12

-31. (canceled)

### Claim 32 (depends on 24)

A method of making a cell comprising transducing a T cell with a vector of claim 24.

### Claim at position 14

-35. (canceled)

### Claim 36

A pharmaceutical composition comprising an anti-tumor effective amount of a population of human T cells, wherein the population of human T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR is encoded by a nucleotide sequence comprising SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, or 82, and wherein the T cells are T cells of a human having a cancer.

### Claim at position 16

-44. (canceled)

### Claim 45

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the population of T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR is encoded by a nucleotide sequence comprising SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, or 82.

### Claim at position 18

-48. (canceled)

### Claim 49 (depends on 45)

The method of claim 45, wherein the cancer is a hematological cancer.

### Claim 50 (depends on 49)

The method of claim 49, wherein the hematological cancer is leukemia, lymphoma, or multiple myeloma.

### Claim 51 (depends on 50)

The method of claim 50, wherein the leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), or chronic myelogenous leukemia (CML).

### Claim 52 (depends on 50)

The method of claim 50, wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.

### Claim 53 (depends on 45)

The method of claim 45, wherein the cancer is an oral and pharynx cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric cancer, a cancer of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, a cancer of the brain, or a combination thereof.
